- Select a blog category
Deloitte’s ‘2016 global health care sector outlook’, launched 14 January, highlights the key global trends impacting the healthcare sector and the important considerations that healthcare stakeholders need to address as they tackle their local marketplace and organisational issues in 2016 and beyond. This week our Centre for Health Solutions blog summarises some of the key considerations covered in the global report which we consider should have implications for the UK.
Today, Thursday 4th February, is Time to Talk Day, aimed at getting the nation talking about mental health. Time to Talk Day is part of Time to Change, a campaign to end the stigma and discrimination that people with mental health problems face in England. The campaign is run by the mental health charities Mind and Rethink Mental Illness, with funding from the Department of Health, Comic Relief and the Big Lottery Fund.
Antibiotics, first prescribed in the mid-1940s, have for many years been seen as the magic bullet to treat infections. However, as quickly as prescribing commenced, antibiotic resistance emerged. In recent years, serious concerns over antibiotic resistance have grown as inadequate control over their use and lack of understanding or monitoring of resistance has led to the emergence of highly resistant strains of bacteria. These concerns continue to amplify, as evidenced in a recent report by Lord Jim O’Neil, the Treasury Minister and former economist, who calls for more investment in rapid diagnosis of bacterial infections to prevent the misuse of antibiotics.i This week’s blog considers the progress in developing and using rapid diagnostic tests to support the prescribing of antibiotics.
This week I’m delighted to be sharing a first-hand account of what it was like to work in A&E on Christmas Eve. This blog has been written by one of our relatively new joiners; a consultant working with the UK Public Sector Business Model Transformation team covering the Healthcare Industry who joined Deloitte following 6 years of medical training, a degree in Healthcare Management and 2.5 years working as a clinician for the NHS, predominantly in accident and emergency services.
Last November our report on Health and Life Science Predictions 2020: a bold future? generated a great deal of interest and enquiry and in the intervening months I have discussed these predictions at numerous sector events, from individual client workshops to high profile sector conferences. Given the pace of change in healthcare, the predictions remain completely prescient however, using the feedback received and on-going tracking of developments, I thought I would use this final blog of 2015 to highlight some of my key healthcare predictions for 2016.
You may have seen the headlines this week that pharma R&D returns are at their lowest level for at least 5 years. This comes from our 6th ‘Measuring the returns from pharmaceutical R&D’ report – an annual study which I have worked on for the last three years. I thought I’d take this opportunity to reflect on the origins of this report and its contribution to the debate on pharma R&D productivity.
World AIDS Day, held on the 1st December each year, provides an opportunity for people to unite in the fight against HIVi and show their support for people living with, or having died as a result of, HIV. At the time of the first World AIDS Day, in 1988, the world was traumatised by HIV as becoming infected was seen as a death sentence. Today, for those with access to treatment, this deathly prognosis has been lifted and indeed the outcome has been largely positive for more than a decade. This weekend, the sudden proliferation of people in the media wearing red ribbons caused me to reflect on the origin of this symbol of support, especially as initially I had to be reminded what it signified. This is turn made me realise that the public campaigning for and media coverage of HIV/AIDS is now much less overt than 10/20 years ago, and consequently people’s awareness may also be diminishing. While this is a renowned global problemii, this week’s blog explores this topic in relation to developments in the UK over these past 30 years.
Now you see it now you don’t: can the Spending Review deliver a sustainable health and social care system?
At 12:30pm on the 25th of November the long awaited and much rehearsed 2015 Spending Review was announced. Speculation about its content has been rife but, as the Chancellor set out how much government funding will be available for the NHS and social care over the next five years, the debate about whether the settlement will be enough to ensure the sustainability of the service commenced. This week’s blog considers the main details of the settlement and discusses what this might mean for health and social care.
This week, the Centre for Health Solutions launched its report The challenge of compliance in life sciences: moving from cost to value at the Financial Times Global Pharmaceutical and Biotechnology Conference in association with Deloitte. The report, which is based on interviews conducted with senior compliance leaders in 11 major life sciences companies and Deloitte’s experience working with the industry, focuses on the compliance challenges life sciences companies face in ensuring a strategic balance between compliance risk and value. As regulators and regulations continue to increase in number and complexity, life sciences companies will need to demonstrate that they have active and comprehensive compliance programmes across all of their business and clinical operations. This week’s blog discusses the seven key insights derived from the initial phase of our research that we believe these programmes would need to address.
This week we’re delighted to feature a blog written by one of our US colleagues. In his ‘My Take’ Reynold W. (Pete) Mooney (Managing Director, Life Sciences and Health Care, Deloitte Touché Tohmatsu Limited) discusses how expanding market access is crucial to providing a sustainable solution to rising healthcare costs.
While infectious disease burden is still a pressing issue around the world, many regions are also facing an explosion of the same chronic and lifestyle diseases that are impacting the developed world. Programs like the US President's Emergency Plan for AIDS Relief (PEPFAR) have enabled great strides against diseases like HIV/AIDS, for example. But sadly, little public money goes toward chronic disease in some parts of the developing world. As a result, more than half of the world’s population makes too little to afford many of the drugs they need, and four out of five chronic disease deaths are in low- or middle-income countries.1,2 These attention-grabbing statistics highlight the vast unmet needs in terms of access and affordability that exist around the globe.